Applied Therapeutics (APLT) Gets a Buy Rating from Robert W. Baird

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Applied Therapeutics (APLTResearch Report) on March 10 and set a price target of $18.00. The company’s shares closed last Friday at $1.59.

According to TipRanks.com, Skorney is ranked 0 out of 5 stars with an average return of -6.6% and a 42.8% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

Applied Therapeutics has an analyst consensus of Hold, with a price target consensus of $14.50.

See the top stocks recommended by analysts >>

Applied Therapeutics’ market cap is currently $44.04M and has a P/E ratio of -0.41.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Read More on APLT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More